AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
Pfizer strikes deal with Chinese online pharmacy JiankePfizer is set to implement a new retail, hospital services and internet healthcare strategy in China as part Share XPfizer strikes deal with Chinese online pharmacy Jiankehttps://pharmaphorum.com/news/pfizer-chinese-online-pharmacy-jianke/
Adaptive Designs in Clinical Trials 2019SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will Share XAdaptive Designs in Clinical Trials 2019https://pharmaphorum.com/events/adaptive-designs-in-clinical-trials-2019/
Merck and Pfizer chalk up another fail for BavencioMerck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in Share XMerck and Pfizer chalk up another fail for Bavenciohttps://pharmaphorum.com/news/merck-and-pfizer-chalk-up-another-fail-for-bavencio/
Pfizer to hike prices of 41 drugs despite Trump criticismPfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, Share XPfizer to hike prices of 41 drugs despite Trump criticismhttps://pharmaphorum.com/news/pfizer-to-hike-prices-of-41-drugs-despite-trump-criticism/
The future of pharma in a digital worldHow is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on Share XThe future of pharma in a digital worldhttps://pharmaphorum.com/digital/healthlive-the-future-of-pharma-in-a-digital-world/
Pfizer hit by UK Supreme Court ruling on Lyrica patentPfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to Share XPfizer hit by UK Supreme Court ruling on Lyrica patenthttps://pharmaphorum.com/news/pfizer-hit-by-uk-supreme-court-ruling-on-lyrica-patent/
FDA green lights Pfizer’s Lorbrena for aggressive lung cancerPfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer. The US Food Share XFDA green lights Pfizer’s Lorbrena for aggressive lung cancerhttps://pharmaphorum.com/news/fda-green-lights-pfizers-lorbrena-for-aggressive-lung-cancer/
Pfizer and Novartis collaborate to find liver disease therapyPfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to Share XPfizer and Novartis collaborate to find liver disease therapyhttps://pharmaphorum.com/news/pfizer-and-novartis-collaborate-to-find-liver-disease-therapy/
